Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models
Elena Ardini(Nerviano Medical Sciences), Maria Menichincheri(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Federico Riccardi Sirtori(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Sonia Troiani(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Antonella Ermoli(Nerviano Medical Sciences), Patrizia Banfi(Nerviano Medical Sciences), Elena Casale, Eduard Felder, Cinzia Cristiani(Politecnico di Milano), Paolo Polucci, Ilaria Motto(Nerviano Medical Sciences), Francesco Caprera(Nerviano Medical Sciences), Alessandra Cirla(Nerviano Medical Sciences), Giulia Canevari(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 1
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury
|Cell Death and Disease|2015|129